Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Plans New U.S. Filing For Xarelto Based On Positive EINSTEIN-PE Results

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

In study of almost 5,000 patients, Janssen/Bayer’s novel anticoagulant proves non-inferior on efficacy compared to old standard of care, with significantly less major bleeding. A mostly one-drug, oral approach could help differentiate the drug from rivals in venous thromboembolism prevention.

You may also be interested in...



Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Rare Disease Roundtable: How Rare Is Too Rare?

Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.

Topics

Related Companies

UsernamePublicRestriction

Register

PS005065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel